drugset / Trial / NCT07541781
Sitagliptin in Recurrent/Progressive Grade 4 Glioma
NaSingle-groupOpen-labelTreatment
Summary
Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.
Timeline
- Start
- 2026-06-11
- Primary completion
- 2029-06-11
- Completion
- 2030-06-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sitagliptin | Small molecule | — | Oral |
| Background | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |